<DOC>
	<DOCNO>NCT01152671</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass safety , tolerability pharmacokinetics RO5024048 . Japanese Caucasian healthy volunteer randomize receive either single oral dos RO5024048 placebo . Follow-up 7-10 day .</brief_summary>
	<brief_title>A Study RO5024048 Japanese Caucasian Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female adult , 20 55 year age , inclusive Body mass index ( BMI ) 18 30 kg/m2 inclusive Nonsmoker , previous smoker discontinue smoke &gt; /= 6 month prior study entry Japanese subject must first generation : bear Japan , live outside Japan &gt; 5 year , able trace maternal paternal Japanese ancestry Female subject childbearing potential male subject partner childbearing potential must agree use two form contraception Agree abstain alcohol consumption strenuous exercise 3 day dose throughout study ( include followup visit ) Positive pregnancy test Males whose female partner pregnant try become pregnant Positive urine test drug abuse Positive alcohol Positive result hepatitis B , hepatitis C , HIV test Clinically significant disease abnormality laboratory parameter Participation investigational drug , biologic device study within 3 month study drug administration Donation loss blood 450 mL within 3 month study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>